These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31318438)

  • 21. "Tumor immunology meets oncology (TIMO) XII", April 28th-30th 2016, Halle/Saale, Germany.
    Seliger B
    Cancer Immunol Immunother; 2017 Nov; 66(11):1497-1503. PubMed ID: 28695228
    [No Abstract]   [Full Text] [Related]  

  • 22. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Customer pyramid framework for CAR T-cell therapies in immuno-oncology.
    Malik NN; Durdy MB
    Drug Discov Today; 2016 Oct; 21(10):1563-1565. PubMed ID: 27640934
    [No Abstract]   [Full Text] [Related]  

  • 24. Editorial (Thematic Issue: Clinical Advances in Immuno-oncology - Progress Towards Selective Cure).
    Liu X; Belani CP
    Curr Mol Pharmacol; 2016; 9(3):182. PubMed ID: 26177639
    [No Abstract]   [Full Text] [Related]  

  • 25. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy.
    Pan C; Liu H; Robins E; Song W; Liu D; Li Z; Zheng L
    J Hematol Oncol; 2020 Apr; 13(1):29. PubMed ID: 32245497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).
    Golan T; Milella M; Ackerstein A; Berger R
    J Exp Clin Cancer Res; 2017 Dec; 36(1):192. PubMed ID: 29282151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of costimulatory and inhibitory receptors in FoxP3
    Toker A; Ohashi PS
    Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy.
    Cushman TR; Caetano MS; Welsh JW; Verma V
    Immunotherapy; 2018 Aug; 10(10):851-0. PubMed ID: 30073899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer immunology and melanoma immunotherapy.
    Linck RDM; Costa RLP; Garicochea B
    An Bras Dermatol; 2017; 92(6):830-835. PubMed ID: 29364441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
    Mooradian MJ; Sullivan RJ
    Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.
    Liberini V; Laudicella R; Capozza M; Huellner MW; Burger IA; Baldari S; Terreno E; Deandreis D
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33920423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Which future for B lymphocytes infiltrating solid tumors: prognostic biomarker and/or therapeutic target?].
    Kaplon H; Dieu-Nosjean MC
    Med Sci (Paris); 2018 Jan; 34(1):72-78. PubMed ID: 29384099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.
    Fu C; Jiang A
    Front Immunol; 2018; 9():3059. PubMed ID: 30619378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The emerging role of epigenetic therapeutics in immuno-oncology.
    Topper MJ; Vaz M; Marrone KA; Brahmer JR; Baylin SB
    Nat Rev Clin Oncol; 2020 Feb; 17(2):75-90. PubMed ID: 31548600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade.
    Wilkinson RW; Leishman AJ
    Front Immunol; 2018; 9():1082. PubMed ID: 29910800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy of cancer in 2012.
    Kirkwood JM; Butterfield LH; Tarhini AA; Zarour H; Kalinski P; Ferrone S
    CA Cancer J Clin; 2012; 62(5):309-35. PubMed ID: 22576456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leveraging NKG2D Ligands in Immuno-Oncology.
    Fuertes MB; Domaica CI; Zwirner NW
    Front Immunol; 2021; 12():713158. PubMed ID: 34394116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Not Available].
    Pasqualini C; Rialland F; Valteau-Couanet D; Michon J; Minard-Colin V
    Bull Cancer; 2018 Dec; 105 Suppl 1():S68-S79. PubMed ID: 30595201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The evolution of interventional oncology in the 21st century.
    Helmberger T
    Br J Radiol; 2020 Sep; 93(1113):20200112. PubMed ID: 32706978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.